H. Zahir

发表

Validation of methods to study the distribution and protein binding of tacrolimus in human blood.

A. McLachlan, H. Zahir, R. A. Nand, 2001, Journal of pharmacological and toxicological methods.

Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors

W. Tap, J. Healey, H. Gelderblom, 2020, Journal of clinical pharmacology.

Use of an Exposure‐Response Model to Aid Early Drug Development of an Oral Sphingosine 1‐Phosphate Receptor Modulator

J. Moberly, S. Rohatagi, K. Truitt, 2009, Journal of clinical pharmacology.

Edoxaban administration following enoxaparin: A pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects

F. Lee, H. Zahir, J. Mendell, 2012, Thrombosis and Haemostasis.

Factors affecting variability in distribution of tacrolimus in liver transplant recipients.

A. McLachlan, G. McCaughan, M. Gleeson, 2003, British journal of clinical pharmacology.

Changes in Tacrolimus Distribution in Blood and Plasma Protein Binding Following Liver Transplantation

A. McLachlan, G. McCaughan, M. Gleeson, 2004, Therapeutic drug monitoring.

Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC

G. Scagliotti, L. Sequist, F. Shepherd, 2014 .

Abstract 1729: An exploratory biomarker analysis evaluating the effect of the c-MET inhibitor tivantinib (ARQ 197) and erlotinib in NSCLC patients in a randomized, double-blinded phase 2 study

L. Sequist, S. Rodig, J. Schiller, 2012 .

Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate

E. Antman, H. Zahir, Ling He, 2015, Circulation.

Phase I studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of DS‐1211, a tissue‐nonspecific alkaline phosphatase inhibitor

J. Stark, H. Zahir, Sonomi Maruyama, 2022, Clinical and translational science.

Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: Results from a 12-week, open-label pilot study in multiple sclerosis patients

T. Vollmer, J. Moberly, H. Zahir, 2012, Journal of Neuroimmunology.

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal

M. Mercuri, J. Levy, H. Zahir, 2016, Critical Care.

CYP2C8-Mediated Formation of a Human Disproportionate Metabolite of the Selective NaV1.7 Inhibitor DS-1971a, a Mixed Cytochrome P450 and Aldehyde Oxidase Substrate

K. Yoshinari, N. Watanabe, H. Zahir, 2021, Drug Metabolism and Disposition.

Metabolism and disposition of [14C]tivantinib after oral administration to humans, dogs and rats

Tomoko Kimura, E. Kamiyama, M. Bathala, 2014, Xenobiotica; the fate of foreign compounds in biological systems.

Abstract 755: A randomized, open-label, phase 1 study to evaluate the effect of food on tivantinib (ARQ 197) pharmacokinetics

Joseph R. Walker, H. Zahir, T. Tokui, 2012 .

Phase 1 Experience of Tivantinib in Patients with Hepatocellular Carcinoma (HCC) or Biliary Tract Cancer (BTC)

B. Schwartz, G. Abbadessa, H. Zahir, 2012 .

Abuse potential of mirogabalin in recreational polydrug users

E. Sellers, H. Zahir, J. Mendell, 2019, Therapeutic advances in drug safety.

Pharmacokinetics, Safety, and Tolerability of Teduglutide, a Glucagon‐Like Peptide‐2 (GLP‐2) Analog, Following Multiple Ascending Subcutaneous Administrations in Healthy Subjects

M. Mouksassi, J. Marier, J. Caminis, 2008, Journal of clinical pharmacology.

Pharmacological Modulation of Peripheral T and B Lymphocytes by a Selective Sphingosine 1‐Phosphate Receptor‐1 Modulator

J. Moberly, S. Rohatagi, K. Truitt, 2012, Journal of clinical pharmacology.

Development and validation of an HPLC-UV method for determination of iohexol in human plasma.

F. Akhlaghi, H. Zahir, Rohit S Soman, 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

First-in-human study of DS-6051b in patients (pts) with advanced solid tumors (AST) conducted in the US.

P. Jänne, A. Shaw, S. Ou, 2018 .

A phase 1 study of efatutazone, an oral peroxisome proliferator‐activated receptor gamma agonist, administered to patients with advanced malignancies

G. Demetri, J. Marshall, M. Pishvaian, 2012, Cancer.

Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies

H. Zahir, J. Mendell, Ling He, 2018, Pharmacology research & perspectives.

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor

F. Lee, H. Zahir, J. Mendell, 2013, American Journal of Cardiovascular Drugs.

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

D. Parasrampuria, K. Truitt, H. Zahir, 2016, British journal of clinical pharmacology.

Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin

G. Senaldi, K. Lasseter, T. Marbury, 2018, Clinical Drug Investigation.

Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours

I. Puzanov, K. Papadopoulos, J. Strickler, 2018, British journal of clinical pharmacology.

Tacrolimus in Diabetic Kidney Transplant Recipients: Pharmacokinetics and Application of a Limited Sampling Strategy

A. Mendonza, F. Akhlaghi, R. Gohh, 2007, Therapeutic drug monitoring.

Population Pharmacokinetic Estimation of Tacrolimus Apparent Clearance in Adult Liver Transplant Recipients

A. McLachlan, F. Akhlaghi, G. McCaughan, 2005, Therapeutic drug monitoring.

(403) Co-administration of mirogabalin and zolpidem in healthy subjects: results from a randomized, double-blind, drug-drug interaction study.

H. Zahir, D. Merante, K. Brown, 2016, The journal of pain : official journal of the American Pain Society.

Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model‐informed Drug Development Strategy

F. LaCreta, O. Yin, H. Zahir, 2023, Clinical pharmacology in drug development.

Effect of coadministration of metformin with mirogabalin: Results from a phase 1, randomized, open-label, drug-drug interaction study .

H. Zahir, Ling He, J. Dow, 2018, International journal of clinical pharmacology and therapeutics.

Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open‐label, drug–drug interaction study

H. Zahir, Ling He, G. Atiee, 2018, British journal of clinical pharmacology.

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects

Kengo Watanabe, F. LaCreta, H. Zahir, 2022, Clinical Pharmacokinetics.

Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics

W. Tap, J. Healey, Li-an Xu, 2022, Journal of clinical pharmacology.

Apparent Clearance of Sirolimus in Heart Transplant Recipients: Impact of Primary Diagnosis and Serum Lipids

A. Keogh, F. Akhlaghi, H. Zahir, 2006, Therapeutic drug monitoring.

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drug‐Drug Interaction Studies in Healthy Subjects

H. Zahir, J. Mendell, Ling He, 2018, Clinical pharmacology in drug development.

Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein

M. Gordon, H. Babiker, F. Kobayashi, 2020, Journal of clinical pharmacology.

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors

J. Hajdenberg, R. Motzer, D. Feldman, 2013, Investigational New Drugs.

Exposure-Response Relationship to Assess the Risk of Neutropenia in Patients With Hepatocellular Carcinoma (HCC) Treated With Tivantinib

Raymond Miller, G. Abbadessa, H. Kastrissios, 2012 .

A phase 1 study of efatutazone, an oral peroxisome proliferator‐activated receptor gamma agonist, administered to patients with advanced malignancies

G. Demetri, J. Marshall, M. Pishvaian, 2012, Cancer.

Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies

H. Zahir, J. Mendell, Ling He, 2018, Pharmacology research & perspectives.